Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Eli Lilly (LLY) reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trading.

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

On February 5, 2024, Eli Lilly and Company (NYSE:LLY) stock closed at $842.18 per share ... during the quarter to manage supply and ensure patient continuity. While shares detracted from ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...